Two obesity drugs are among the six new medications that could get faster FDA review under a new pilot program open to products addressing certain national health priorities.

Rare and infectious diseases as well as cancer are the other therapeutic areas covered by the new batch of voucher recipients. The vouchers announced Thursday come three weeks after the FDA unveiled the first nine drugs selected for this Commissioner’s National Priority Voucher (CNPV) program . Eligible products must meet criteria such as improving affordability or increasing domestic manufacturing. Another consideration is addressing an unmet public health need.

The obesity drugs awarded vouchers are Novo Nordisk’s injectable GLP-1 drug Wegovy, and Eli Lilly’s oral GLP-1 drug orforglipron. While Wegovy is alrea

See Full Page